IN THE SPOTLIGHT

Combining Osimertinib and Chemotherapy Improves Progression-Free Survival for Advanced Lung Cancer Patients

Combining Osimertinib and Chemotherapy Improves Progression-Free Survival for Advanced Lung Cancer Patients

Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC

Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC

Certain NSCLC Subgroups May Not Benefit From Immunotherapy

Certain NSCLC Subgroups May Not Benefit From Immunotherapy

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Benjamin Besse, MD, PhD, on EGFR-Mutated NSCLC: Update on Patritumab Deruxtecan in Previously Treated Disease

Benjamin Besse, MD, PhD, on EGFR-Mutated NSCLC: Update on Patritumab Deruxtecan in Previously Treated Disease

POSing the question: MARIPOSA-2, do the ends justify the means?

POSing the question: MARIPOSA-2, do the ends justify the means?

The current status and future of ADC therapy for small cell Lung Cancer: a promising approach

The current status and future of ADC therapy for small cell Lung Cancer: a promising approach

Lung Cancer News From 2023

Lung Cancer News From 2023

AstraZeneca lung and breast cancer data at WCLC and ESMO 2021 underscore ambition to revolutionise outcomes for patients

AstraZeneca lung and breast cancer data at WCLC and ESMO 2021 underscore ambition to revolutionise outcomes for patients

Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies

Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies